更新于：2024-05-01
Parecoxib Sodium
帕瑞昔布钠
更新于：2024-05-01
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2002-03-22), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C19H18N2O4S |
InChIKeyTZRHLKRLEZJVIJ-UHFFFAOYSA-N |
CAS号198470-84-7 |
查看全部结构式(2)
关联
106
项与 帕瑞昔布钠 相关的临床试验Parecoxib Versus Morphine in Acute Pain Management for Sickle Cell Disease Patients in Emergency Department: A Randomized Controlled Trial.
Introduction: This study focuses on the treatment of painful crises in Sickle Cell Disease (SCD) patients using Paracoxib, a non-opioid, compared to Morphine. It addresses the need for alternative medications that reduce opioid dependency while providing effective analgesia.
Objectives:
Primary: Evaluate the analgesic effect of Paracoxib versus Morphine in SCD vaso-occlusive crises.
Secondary: Reduce opioid use/dependence, decrease the length of hospital stays, and monitor side effects related to Paracoxib.
Methodology: A double-blinded randomized controlled trial, conducted in a tertiary care emergency department. The study includes adult SCD patients with moderate to severe crises, excluding non-VOC pain, certain medications, and specific medical conditions. The sample size is 226 patients, split equally into two groups.
Intervention: Patients receive either Morphine or Paracoxib, with periodic assessment of vital signs and pain. Additional Morphine is administered if required. Data collection and analysis are meticulously planned.
Expected Outcomes: Improvement in SCD pain management, reduction in opioid usage, and potential benefits in terms of hospital stays and patient satisfaction.
Objectives:
Primary: Evaluate the analgesic effect of Paracoxib versus Morphine in SCD vaso-occlusive crises.
Secondary: Reduce opioid use/dependence, decrease the length of hospital stays, and monitor side effects related to Paracoxib.
Methodology: A double-blinded randomized controlled trial, conducted in a tertiary care emergency department. The study includes adult SCD patients with moderate to severe crises, excluding non-VOC pain, certain medications, and specific medical conditions. The sample size is 226 patients, split equally into two groups.
Intervention: Patients receive either Morphine or Paracoxib, with periodic assessment of vital signs and pain. Additional Morphine is administered if required. Data collection and analysis are meticulously planned.
Expected Outcomes: Improvement in SCD pain management, reduction in opioid usage, and potential benefits in terms of hospital stays and patient satisfaction.
开始日期2024-05-01 |
申办/合作机构 |
To investigate the effect of traditional Chinese medicine five elements music therapy combined with parecoxib on painless induced abortion before operation
开始日期2024-03-01 |
申办/合作机构- |
Preoperative application of Parecoxib can alleviate postoperative pain of early esophageal cancer after ESD by reducing inflammatory response
开始日期2024-02-01 |
申办/合作机构 |
100 项与 帕瑞昔布钠 相关的临床结果
登录后查看更多信息
100 项与 帕瑞昔布钠 相关的转化医学
登录后查看更多信息
100 项与 帕瑞昔布钠 相关的专利（医药）
登录后查看更多信息
646
项与 帕瑞昔布钠 相关的文献（医药）2024-02-14·European journal of pharmacology
Parecoxib sodium attenuates acute lung injury following burns by regulating M1/M2 macrophage polarization through the TLR4/NF-κB pathway.
Article
作者: Dongxiao Huang ; Zhongjun Zhang ; Jinjin Jian ; Xuliang Jiang ; Jie Gao ; Minlie Yang ; Xian Ding
High temperature-induced burn injury often leads to an excessive inflammatory cascade resulting in multiple organ dysfunction syndrome, such as acute lung injury (ALI), in addition to skin tissue damage. As a specific COX2 inhibitor, parecoxib sodium suppresses the inflammatory response during burn injury. The effect of parecoxib sodium on ALI induced by burn injury and the associated molecular mechanism still need to be investigated. The role of parecoxib sodium in burn injury-induced ALI through the TLR4/NF-κB pathway was explored in the present study. A burn-induced ALI mouse model was constructed, and M1/M2 macrophages in lung tissue and markers involved in the TLR4/NF-κB signalling pathway were evaluated in bronchoalveolar lavage fluid (BALF) and MH-S mouse alveolar macrophages in vitro. The results indicated that parecoxib sodium attenuated lung injury after burn injury, decreased iNOS and TNF-α expression, increased IL-10 expression in BALF, and regulated the CD86-and CD206-mediated polarization of M1/M2 macrophages in lung tissue along with MH-S mouse alveolar macrophages. The effect of parecoxib sodium might be reversed by a TLR4 agonist. Overall, the results suggested that parecoxib sodium can regulate the polarization of M1/M2 macrophages through the TLR4/NF-κB pathway to attenuate ALI induced by skin burns.
2024-01-01·European review for medical and pharmacological sciences
Effects of parecoxib on postoperative cognitive dysfunction and serum levels of NSE and S100β in elderly patients undergoing surgery.
Article
作者: W-Y Yin ; T Peng ; B-C Guo ; C-C Fan ; J Xu ; X-M Liu ; X Li
OBJECTIVE:
To investigate the effects of parecoxib on postoperative cognitive dysfunction, and serum levels of neuron-specific enolase (NSE) and S100β protein (S100β) in elderly patients undergoing surgery.
PATIENTS AND METHODS:
The retrospective cohort study method was used to collect the clinical data of 94 elderly patients who underwent elective orthopedic and general anesthesia surgery in our hospital from September 2020 to February 2022. 94 patients were divided into the control group (47 cases) and the study group (47 cases), according to different intervention methods. In the study group, 40 mg of parecoxib was injected intravenously into patients 30 min before the induction of anesthesia, and the patients in the control group were given the same dose of normal saline intravenously before the operation. The basic clinical data of the patients were collected. The levels of the indexes before operation and 6 hours after operation were compared between the two groups, including the Montreal Cognitive Scale (MoCA) score, inflammatory factor indicators [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), interleukin-10 (IL-10), interleukin-1β (IL-1β), monocyte chemokine-1 (MCP-1), and inducible nitric oxide synthase (iNOS)], serum cortisol (CORT), beta-amyloid (β-AP), adiponectin (ADP), NSE, and S100β.
RESULTS:
No significant differences in the preoperative MoCA score, TNF-α, IL-6, CRP, IL-10, IL-1β, MCP-1, iNOS, CORT, β-AP, ADP, NSE, and S100β levels were observed between the two groups (p>0.05). The postoperative MoCA score in the study group was significantly higher than that in the control group (p<0.05). The postoperative levels of TNF-α, IL-6, CRP and IL-1β in the study group were significantly lower than those in the control group (p<0.05), and the postoperative levels of IL-10, MCP-1 and iNOS in the study group were significantly higher than those in the control group (p<0.05).
CONCLUSIONS:
Parecoxib can notably inhibit the levels of postoperative inflammatory cytokines, improve neurological dysfunction, and reduce the occurrence of postoperative cognitive dysfunction in patients. The contents of serum NSE and S100β have potential value in the diagnosis of postoperative cognitive dysfunction in elderly patients.
2024-01-01·International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy.
Article
作者: Chih-Chung Cheng ; Hung-Chieh Yeh ; Pei-Wen Su ; Chien-Lin Ho ; Sheng-Chi Chang
PURPOSE:
Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors.
MATERIALS AND METHODS:
From January 2016 to August 2021, a total of 55 patients treated with CRS and cisplatin-based HIPEC for peritoneal carcinomatosis were categorized retrospectively into groups, with and without CKD. Demographics, comorbidity, surgery, postoperative management, and complications were collected to evaluate risk factors for cisplatin-based HIPEC-related CKD. Univariate and multivariate analyses were conducted to confirm the correlation between different variables and CKD occurrence.
RESULTS:
Of the 55 patients, 24 (43.6%) patients developed AKI and 17 (70.8%) patients of these AKI patients progressed to CKD. Multivariate regression analysis identified intraoperative use of parecoxib (Odds Ratio (OR) = 4.39) and intraoperative maximum temperature > 38.5°C (OR = 6.40) as major risk factors for cisplatin-based HIPEC-related CKD occurrence. Though type II diabetes mellitus and intraoperative complications were the independent risk factors of AKI following cisplatin-based HIPEC, but they were not shown in CKD analysis.
CONCLUSION:
Intraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC.
75
项与 帕瑞昔布钠 相关的新闻（医药）2024-03-18
·信狐药迅
每周药品注册获批数据，分门别类呈现，一目了然。（3.11-3.17）新药上市申请药品名称企业注册分类受理号妥拉美替尼胶囊上海科州药物研发有限公司1CXHS2300033妥拉美替尼胶囊上海科州药物研发有限公司1CXHS2300032拈痛祛风颗粒成都华西天然药物有限公司1.1CXZS2200013舒格利单抗注射液辉瑞投资有限公司2.2CXSS2300007硫酸阿托品滴眼液沈阳兴齐眼药股份有限公司2.4CXHS2300047安纳白介素注射液(预充式)Swedish Orphan Biovitrum AB (publ)3.1JXSS2200034佩索利单抗注射液(皮下注射)Boehringer Ingelheim International GmbH2.2;2.1JXSS2300039新药临床申请药品名称企业注册分类受理号SYH2039片石药集团中奇制药技术(石家庄)有限公司1CXHL2400030SYH2039片石药集团中奇制药技术(石家庄)有限公司1CXHL2400029ABBV-383输注用溶液AbbVie Inc.1JXSL2400007TarlatamabAmgen Inc.1JXSL2400004TarlatamabAmgen Inc.1JXSL2400005TarlatamabAmgen Inc.1JXSL2400006洛奈利单抗注射液山东新时代药业有限公司1CXSL2400008注射用SIM0500上海先祥医药科技有限公司1CXSL2400001IBI129信达生物制药(苏州)有限公司1CXSL2400006INV-1120胶囊佛山市原力生物科技有限公司1CXHL2301483INV-1120胶囊佛山市原力生物科技有限公司1CXHL2301482GT919胶囊标新生物医药科技(上海)有限公司1CXHL2301479GT919胶囊标新生物医药科技(上海)有限公司1CXHL2301478GT919胶囊标新生物医药科技(上海)有限公司1CXHL23014773HP-2827片思康睿奇(苏州)药业有限公司1CXHL23014853HP-2827片思康睿奇(苏州)药业有限公司1CXHL2301484注射用BAT8008百奥泰生物制药股份有限公司1CXSL2300907BAT1308注射液百奥泰生物制药股份有限公司1CXSL2300906M1774胶囊Merck Healthcare KGaA1JXHL2300330M1774胶囊Merck Healthcare KGaA1JXHL2300329SCTB35注射液神州细胞工程有限公司1CXSL2300900注射用重组抗PD1/TIM3人源化双特异抗体上海健信生物医药科技有限公司1CXSL2300899注射用LB4330上海健信生物医药科技有限公司1CXSL2300898JL18008注射液杰库(上海)生物医药研究有限公司1CXSL2300897WS-0101溶液北京厚燊维康科技有限责任公司1CXHL2301464ICP-248片北京诺诚健华医药科技有限公司1CXHL2301461ICP-248片北京诺诚健华医药科技有限公司1CXHL2301460注射用BL-M05D1成都百利多特生物药业有限责任公司1CXSL2300904NS-041分散片纽欧申医药(上海)有限公司1CXHL2301454NS-041分散片纽欧申医药(上海)有限公司1CXHL2301453BI1569912 片Boehringer Ingelheim International GmbH1JXHL2300328BI1569912 片Boehringer Ingelheim International GmbH1JXHL2300327HLX6018上海复宏汉霖生物技术股份有限公司1CXSL2300889VIC-1911片捷思英达医药技术(上海)有限公司1CXHL2301448注射用AST2169脂质体上海艾力斯医药科技股份有限公司1CXHL2301442EtavopivatNovo Nordisk A/S1JXHL2300326Aficamten片Cytokinetics, Incorporated1JXHL2300325ALXN2220注射液阿斯利康全球研发(中国)有限公司1CXSL2300880HDM1005注射液杭州中美华东制药有限公司1CXHL2301440HDM1005注射液杭州中美华东制药有限公司1CXHL2301439HDM1005注射液杭州中美华东制药有限公司1CXHL2301438HDM1005注射液杭州中美华东制药有限公司1CXHL2301437ANG-0623胶囊嘉兴和剂药业有限公司1CXHL2301436ANG-0623胶囊嘉兴和剂药业有限公司1CXHL2301435Zibotentan达格列净片AstraZeneca AB1JXHL2300317Zibotentan达格列净片AstraZeneca AB1JXHL2300316ENN0403胶囊轶诺(浙江)药业有限公司1CXHL2301411ENN0403胶囊轶诺(浙江)药业有限公司1CXHL2301414ENN0403胶囊轶诺(浙江)药业有限公司1CXHL2301413人脂肪间充质干细胞注射液北京瑷格干细胞科技有限公司1CXSL2300857Cemdisiran注射液Regeneron Pharmaceuticals, Inc.1JXHL2300313GC012F注射液苏州亘喜生物科技有限公司1CXSL2300855YFQLXB-UC01注射液山东省齐鲁细胞治疗工程技术有限公司1CXSL2300854PT199凡恩世制药(北京)有限公司1CXSL2300815铁皮石斛咀嚼片杭州丹鹤医药有限公司1.1CXZL2300075DS-8201aDaiichi Sankyo, Inc.2.2JXSL2400011TAR-200Janssen Research & Development, LLC2.2JXHL2400002注射用罗特西普Celgene Corporation2.2JXSL2400003注射用罗特西普Celgene Corporation2.2JXSL2400002cemiplimabRegeneron Ireland Designated Activity Company (DAC)2.2JXSL2300237小儿泼尼松肠溶干混悬剂文韬创新药物研究(北京)有限责任公司2.2CXHL2301452Benralizumab注射液AstraZeneca AB2.2JXSL2300235SH081012口服用浓溶液山东百诺医药股份有限公司2.2CXHL2301441马来酸奈拉替尼片甫康(上海)健康科技有限责任公司2.4CXHL2400045索凡替尼胶囊和记黄埔医药(上海)有限公司2.4CXHL2400018盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHL2400006盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHL2400007盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHL2400008布地格福吸入气雾剂AstraZeneca AB2.4JXHL2300324QL2109注射液齐鲁制药有限公司3.3CXSL2400011司美格鲁肽注射液成都倍特生物制药有限公司3.3CXSL2300894司美格鲁肽注射液成都倍特生物制药有限公司3.3CXSL2300893司美格鲁肽注射液成都倍特生物制药有限公司3.3CXSL2300892注射用替妥木单抗浙江博崤生物制药有限公司3.4CXSL2300873人凝血因子VIII四川远大蜀阳药业有限责任公司3.4CXSL2300862仿制药申请药品名称企业注册分类受理号酮咯酸氨丁三醇注射液四川诺非特生物药业科技有限公司3CYHS2301094布洛芬注射液山西德元堂药业有限公司3CYHS2301016布洛芬注射液山西德元堂药业有限公司3CYHS2301015重酒石酸去甲肾上腺素注射液成都欣捷高新技术开发股份有限公司3CYHS2201851重酒石酸去甲肾上腺素注射液成都欣捷高新技术开发股份有限公司3CYHS2201850复方α-酮酸片北京康而福药业有限责任公司3CYHS2201722阿立哌唑口服溶液锦州奥鸿药业有限责任公司3CYHS2201506阿立哌唑口服溶液锦州奥鸿药业有限责任公司3CYHS2201507氨溴特罗口服溶液江苏广承药业有限公司3CYHS2201487氨溴特罗口服溶液浙江寰领医药科技有限公司3CYHS2201271吸入用硫酸沙丁胺醇溶液立生医药(苏州)有限公司3CYHS2201258吸入用硫酸沙丁胺醇溶液立生医药(苏州)有限公司3CYHS2201257盐酸多巴酚丁胺注射液杭州云柏医药科技有限公司3CYHS2201202米诺地尔外用溶液中山万汉制药有限公司3CYHS2201144米诺地尔外用溶液中山万汉制药有限公司3CYHS2201143阿立哌唑口服溶液浙江百代医药科技有限公司3CYHS2201119阿立哌唑口服溶液浙江百代医药科技有限公司3CYHS2201118阿立哌唑口服溶液浙江百代医药科技有限公司3CYHS2201117阿立哌唑口服溶液浙江百代医药科技有限公司3CYHS2201116米诺地尔外用溶液江苏万高药业股份有限公司3CYHS2200862米诺地尔外用溶液江苏万高药业股份有限公司3CYHS2200861阿立哌唑口服溶液西洲医药科技(浙江)有限公司3CYHS2200776冻干人用狂犬病疫苗(Vero细胞)复星雅立峰(大连)生物制药有限公司3.3CXSS2200072依折麦布辛伐他汀片浙江诺得药业有限公司4CYHS2400091洛索洛芬钠凝胶膏浙江赛默制药有限公司4CYHL2300159恩曲他滨丙酚替诺福韦片(I)华北制药华坤河北生物技术有限公司4CYHS2300940盐酸胺碘酮注射液浙江普利药业有限公司4CYHS2300798二甲硅油乳剂江苏亚尧生物科技有限公司4CYHS2300735奥美拉唑镁肠溶片重庆莱美药业股份有限公司4CYHS2300131阿司匹林肠溶片江苏必易生物科技有限公司4CYHS2202152雷贝拉唑钠肠溶片河北朴舟药业有限公司4CYHS2202016哌柏西利胶囊先声药业有限公司4CYHS2201989哌柏西利胶囊先声药业有限公司4CYHS2201988哌柏西利胶囊先声药业有限公司4CYHS2201986马昔腾坦片南京泽恒医药技术开发有限公司4CYHS2201679注射用帕瑞昔布钠陕西博森生物制药股份集团有限公司4CYHS2201471注射用帕瑞昔布钠陕西博森生物制药股份集团有限公司4CYHS2201470地夸磷索钠滴眼液江苏万高药业股份有限公司4CYHS2201453盐酸帕洛诺司琼注射液山东齐都药业有限公司4CYHS2201441盐酸帕洛诺司琼注射液山东齐都药业有限公司4CYHS2201440枸橼酸西地那非片南昌立健药业有限公司4CYHS2201396苯磺酸左氨氯地平片河北朴舟药业有限公司4CYHS2201358苯磺酸左氨氯地平片河北朴舟药业有限公司4CYHS2201357盐酸帕洛诺司琼注射液华夏生生药业(北京)有限公司4CYHS2201350注射用达托霉素深圳立健药业有限公司4CYHS2201298吸入用硫酸沙丁胺醇溶液立生医药(苏州)有限公司4CYHS2201259莫匹罗星软膏山东良福制药有限公司4CYHS2201264盐酸氮卓斯汀滴眼液南京恒道医药科技股份有限公司4CYHS2201080他达拉非片广州博济生物医药科技园有限公司4CYHS2201077布洛芬缓释胶囊山东新华制药股份有限公司4CYHS2200983奥美沙坦酯片吉林亚泰永安堂药业有限公司4CYHS2200856奥美沙坦酯片吉林亚泰永安堂药业有限公司4CYHS2200855普瑞巴林胶囊宁波双成药业有限公司4CYHS2200452普瑞巴林胶囊宁波双成药业有限公司4CYHS2200451玻璃酸钠滴眼液上海昊海生物科技股份有限公司4CYHS2200383普瑞巴林胶囊澳美制药(海南)有限公司4CYHS2200233普瑞巴林胶囊澳美制药(海南)有限公司4CYHS2200232卡前列素氨丁三醇注射液博瑞制药(苏州)有限公司4CYHS2200070普瑞巴林胶囊重庆医药(集团)股份有限公司4CYHS2101936普瑞巴林胶囊重庆医药(集团)股份有限公司4CYHS2101935进口申请药品名称企业注册分类受理号ABBV-383输注用溶液AbbVie Inc.1JXSL2400007TarlatamabAmgen Inc.1JXSL2400004TarlatamabAmgen Inc.1JXSL2400005TarlatamabAmgen Inc.1JXSL2400006M1774胶囊Merck Healthcare KGaA1JXHL2300330M1774胶囊Merck Healthcare KGaA1JXHL2300329BI1569912 片Boehringer Ingelheim International GmbH1JXHL2300328BI1569912 片Boehringer Ingelheim International GmbH1JXHL2300327EtavopivatNovo Nordisk A/S1JXHL2300326Aficamten片Cytokinetics, Incorporated1JXHL2300325Zibotentan达格列净片AstraZeneca AB1JXHL2300317Zibotentan达格列净片AstraZeneca AB1JXHL2300316Cemdisiran注射液Regeneron Pharmaceuticals, Inc.1JXHL2300313DS-8201aDaiichi Sankyo, Inc.2.2JXSL2400011TAR-200Janssen Research & Development, LLC2.2JXHL2400002注射用罗特西普Celgene Corporation2.2JXSL2400003注射用罗特西普Celgene Corporation2.2JXSL2400002cemiplimabRegeneron Ireland Designated Activity Company (DAC)2.2JXSL2300237Benralizumab注射液AstraZeneca AB2.2JXSL2300235布地格福吸入气雾剂AstraZeneca AB2.4JXHL2300324安纳白介素注射液(预充式)Swedish Orphan Biovitrum AB (publ)3.1JXSS2200034佩索利单抗注射液(皮下注射)Boehringer Ingelheim International GmbH2.2;2.1JXSS2300039中药相关申请药品名称企业注册分类受理号铁皮石斛咀嚼片杭州丹鹤医药有限公司1.1CXZL2300075拈痛祛风颗粒成都华西天然药物有限公司1.1CXZS2200013注：灰色字体部分结论为不批准或收到通知件；
上市批准申请上市
2024-03-11
·药通社
刚刚，NMPA发布2024年03月11日药品批准证明文件送达信息，本批次共有65个受理号获批，其中3个为一致性评价受理号，过评品种为：遂成药业股份有限公司，盐酸氨溴索注射液湖南科伦制药有限公司，注射用哌拉西林钠默晨制药（湖北）有限公司，硝酸异山梨酯注射液本次另有31个上市申请受理号获批，涉及十余个品种，包括：重庆医药的普瑞巴林胶囊；江苏万高药业的米诺地尔搽剂；山东新华制药的布洛芬缓释胶囊；广州博济生物的他达拉非片；陕西博森生物制药的注射用帕瑞昔布钠；南京泽恒医药的马昔腾坦片；先声再明医药的哌柏西利胶囊等此外，沈阳兴齐眼药股份有限公司的2.4类新药硫酸阿托品滴眼液获批上市，拟用于延缓儿童近视进展。2023年5月，兴齐眼药的硫酸阿托品滴眼液因符合儿童生理特征的儿童用药品新品种、剂型和规格”，被纳入优先审评审批程序。山东新华制药的布洛芬缓释胶囊获批上市，视同通过一致性评价。勃林格殷格翰的佩索利单抗注射液（皮下注射）获批上市，用于减少12岁及以上青少年（体重≥40 kg）和成人的泛发性脓疱型银屑病（Generalized Pustular Psoriasis，简称GPP）发作。佩索利单抗是同类首个阻断白介素-36受体 (IL-36R)激活的单克隆抗体，可针对性抑制与GPP发作密切相关的白细胞介素-36（IL-36）通路，通过与IL-36受体结合，阻断IL-36产生的炎症反应，从而抑制GPP的炎症信号通路，实现脓疱和皮损的快速清除，减少GPP发作。此前2022年12月，佩索利单抗静脉注射制剂已在中国获批用于治疗成人GPP发作。欢迎添加微信，进入批件之家仅供交流，与官方无关
上市批准优先审批一致性评价
2024-02-27
·赛柏蓝
作者 | 陈芋来源 | 赛柏蓝01642个药品降价最高下调金额超4200元 2月27日，河南省公共资源交易中心发布《关于洁阴康洗液等115个下调挂网价格药品的公示》，公示期为即日起至2月29日（具体名单见文末附1）。 河南此批调价名单中，下调金额最大的药品为杭州中美华东的马昔腾坦片，从3726元降至2969元，下调757元；成都倍特的仑伐替尼、丙酚替诺福韦为名单中下调金额第二、第三大的药品，价格分别下调321.1元、99.8元。 河南该名单中115个药品的平均价格下调幅度约11.48%，除上述3个药品外，其余112个药品下调金额均不超过50元。 此前，辽宁也公布了527个药品的调整情况（具体名单见文末附2），最新降价结果自2月28日起会在全省所有医疗卫生机构执行。 名单显示，527个药品中有4个药品价格下调超千元。 重庆圣华曦的甲磺酸伊马替尼片是其中下调金额最大的药品，从4860元降至585.9元，下调4274.1元；先声药业的注射用培美曲塞二钠、闽东力捷迅的注射用特利加压素、杭州和泽坤元的醋酸阿比特龙片价格下调金额在1300余元至1100余元不等。 另有10款药品的价格下调超过500元；30款药品的价格下调超过100元；此外，还有217个药品价格下调不高于1元，约占总数的四成。 价格降幅方面，此次在辽宁调价的527个药品价格平均降幅约16.24%，除去价格下调不高于1元的217个药品后，平均降幅约26.04%。 降幅超过90%的药品共8个，均为注射液，覆盖缩宫素注射液、胞磷胆碱钠注射液、盐酸多巴胺注射液、注射用帕瑞昔布钠、烟酰胺注射液5个品种，其中石家庄四药的胞磷胆碱钠注射液降幅最大，达到98.61%，价格从183元调至2.54元。 不止是河南和辽宁，湖北、广西近期据国家医保局《关于通报部分价格虚高药品约谈结果并抓好落实的函》《关于部分药品耗材价格问题整改结果的通报》内容接连发布通知，要求相关企业将产品价格下调至不高于整改后的挂网价格，并且广西明确强调不得以撤网替代降价。02全国价格协同3月底前完成19省已行动 今年年初，国家医保局下发《关于促进同通用名同厂牌药品省际间价格公平诚信、透明均衡的通知》，要求对照挂网监测价，在今年3月底前，消除省际间的歧视性高价。 2月27日，西藏自治区药品采购服务管理中心发布《关于开展已挂网药品价格协同工作的通知》，成为继广东、山东、四川等省之后第19个开展价格协同工作的省级行政区，价格协同自即日起至3月10日期间进行。 各省价格调整要求及企业操作方式存在一定差异，西藏此次调价规则与四川类似，按照集采批次作出划分—— 对于3月10日后仍存在以不公平高价、歧视性高价挂网现象的药品，一经核实，西藏直接对相关企业进行通报和约谈。经约谈拒绝纠正偏高价格的企业，将依据《医药价格和招采信用裁量基准（2020版）》进行下一步处理，直至取消挂网资格。 目前，仍有十余省暂未公布相关工作安排，但按照国家医保局今年3月底前消除省际间歧视性高价的要求，未来一个月内，各省相关动作都将密集展开。 目前，全国针对挂网价格治理仅涉及“四同药品”，预计后续还将有同厂家不同规格包装的价格协同，直至同品种不同厂家的价格协同等，3月底之后，挂网价格治理仍将持续进行。附1：河南关于洁阴康洗液等115个下调挂网价格药品的公示附2：辽宁烟酰胺注射液等527个药品调整清单END内容沟通：13810174402医药代表交流群扫描下方二维码加入银发经济市场机遇交流群扫描下方二维码加入左下角「关注账号」，右下角「在看」，防止失联
带量采购一致性评价生物类似药
100 项与 帕瑞昔布钠 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 术后疼痛 | 批准上市 | 中国 更多 | |
| 疼痛 | 无进展 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 213 | (鹽遞觸鹹遞鹽構廠襯憲) = 壓壓膚鹹顧簾齋鹽淵鹽 膚夢淵窪廠憲廠壓選衊 (獵鬱鹹廠窪憲艱鬱蓋範 ) | 积极 | 2020-02-04 | |||
(鹽遞觸鹹遞鹽構廠襯憲) = 襯顧獵遞鹽範夢簾壓範 膚夢淵窪廠憲廠壓選衊 (獵鬱鹹廠窪憲艱鬱蓋範 ) | |||||||
N/A | - | 620 | 鏇鏇築窪繭網鏇齋築範(網鏇鹹遞鹹衊顧醖糧鏇) = 壓鏇觸鑰醖餘鬱選築廠 齋廠壓築衊廠網壓醖築 (醖製遞齋膚觸鑰蓋鬱觸, 0.33 ~ 0.96) | 积极 | 2017-06-01 | ||
Placebo | 鏇鏇築窪繭網鏇齋築範(網鏇鹹遞鹹衊顧醖糧鏇) = 選鬱範齋築鏇鑰膚糧範 齋廠壓築衊廠網壓醖築 (醖製遞齋膚觸鑰蓋鬱觸 ) | ||||||
N/A | - | Parecoxib sodium + TAP block | (鹽淵衊窪積鏇廠膚獵餘) = No significant differences were found between the two groups related to adverse events 遞鏇範積鏇積鏇餘衊壓 (網鏇艱憲夢製製餘鏇餘 ) 更多 | 积极 | 2020-09-13 | ||
临床3期 | 80 | (淵網遞醖餘觸願淵顧膚) = 醖鹹簾顧蓋鏇鬱網窪簾 簾構廠獵醖構繭鬱蓋醖 (鏇襯範艱淵築淵鹽蓋構, 9.8 ~ 28.2) 更多 | 积极 | 2020-09-13 | |||
Placebo | (淵網遞醖餘觸願淵顧膚) = 夢鑰鹽蓋鬱窪願醖膚顧 簾構廠獵醖構繭鬱蓋醖 (鏇襯範艱淵築淵鹽蓋構, 8.1 ~ 19.9) 更多 | ||||||
临床4期 | - | (窪糧夢蓋築艱糧製簾簾) = 膚齋獵鑰鹹觸製築鹽製 觸廠遞衊獵蓋淵繭遞膚 (淵衊鬱衊醖選簾觸範憲 ) | 不佳 | 2011-09-01 | |||
Placebo | (窪糧夢蓋築艱糧製簾簾) = 積鏇糧壓獵艱夢繭願夢 觸廠遞衊獵蓋淵繭遞膚 (淵衊鬱衊醖選簾觸範憲 ) | ||||||
临床4期 | 105 | 憲製蓋範鏇鏇醖襯鬱鏇(選窪鏇淵膚鑰願艱餘衊) = 鏇繭願廠鏇獵築糧網夢 衊淵廠鏇遞齋艱選繭夢 (鑰願艱簾憲選願壓築憲, 24.1) 更多 | 积极 | 2015-03-09 | |||
Morphine+Placebo | 憲製蓋範鏇鏇醖襯鬱鏇(選窪鏇淵膚鑰願艱餘衊) = 蓋願簾製構願鹹醖窪餘 衊淵廠鏇遞齋艱選繭夢 (鑰願艱簾憲選願壓築憲, 28) 更多 | ||||||
N/A | - | 240 | 鑰顧壓獵製衊鏇築鹹夢(築顧簾鏇鹽繭糧膚衊獵) = 選範襯願憲壓遞壓齋網 製齋網淵鏇鑰選遞觸鏇 (壓膚淵選簾憲憲壓顧夢 ) 更多 | 积极 | 2016-01-01 | ||
Placebo | 鑰顧壓獵製衊鏇築鹹夢(築顧簾鏇鹽繭糧膚衊獵) = 醖鬱鑰構襯餘繭淵獵築 製齋網淵鏇鑰選遞觸鏇 (壓膚淵選簾憲憲壓顧夢 ) 更多 | ||||||
临床2期 | - | - | 鹽憲蓋襯壓網鏇衊獵選(蓋鹽築齋廠糧衊構網餘) = 觸廠顧壓夢艱齋糧範蓋 齋鑰製憲鑰觸艱選簾憲 (壓醖衊網範遞範網築艱 ) | 不佳 | 2009-01-01 | ||
Placebo | 鹽憲蓋襯壓網鏇衊獵選(蓋鹽築齋廠糧衊構網餘) = 積蓋獵餘築範積襯鑰膚 齋鑰製憲鑰觸艱選簾憲 (壓醖衊網範遞範網築艱 ) | ||||||
临床4期 | 340 | (Parecoxib) | 壓鏇鑰衊壓獵衊餘艱遞(醖繭淵願繭獵觸窪夢膚) = 製選獵淵繭鹽襯膚顧廠 淵鹽遞鹽遞選製觸願繭 (糧蓋願築製衊顧築顧餘, 顧醖築廠鹽壓襯餘鹹鹽 ~ 淵壓製憲鬱鏇憲蓋鏇壓) 更多 | - | 2013-01-28 | ||
(Ketoprofen) | 壓鏇鑰衊壓獵衊餘艱遞(醖繭淵願繭獵觸窪夢膚) = 構選窪觸夢鏇繭積糧襯 淵鹽遞鹽遞選製觸願繭 (糧蓋願築製衊顧築顧餘, 淵範鹽選網範繭網鬱製 ~ 衊餘壓齋遞廠夢構淵廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
标准版
¥16800
元/账号/年
新药情报库 ｜ 省钱又好用！
立即使用
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用